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Selective application of sartorius muscle flaps and
aggressive staged surgical debridement can
influence long-term outcomes of complex
prosthetic graft infections
Paul A. Armstrong, DO, Martin R. Back, MD, Dennis F. Bandyk, MD, Brad L. Johnson, MD, and
Murray L. Shames, MD, Tampa, Fla
Background:The complexity of variables associated with vascular surgical site infections (VSSI) often contribute adversely
to reinfection, limb salvage, and mortality rates. This report details our experience with the selective use of a sartorius
muscle flaps (SMF) as part of an overall treatment strategy focused on staged surgical debridement (SSD) to control
prosthetic graft bed infection prior to a graft preservation or revision plan.
Methods: From our vascular registry, we identified 422 VSSI of which 89 (21%) had SMF for 24 aorto-bifemoral (ABF),
19 extra-anatomic bypasses (EAB), 34 infrainguinal bypasses, and 12 combined inflow/outflow reconstructions. All 86
patients had Szilagyi grade III prosthetic (Dacron-36, polytetrafluoroethylene [PTFE]-50) graft infections. The
treatment algorithm included: SSD, culture-directed parenteral antibiotics, graft preservation (n 3), or reconstruction
(graft excision/EAB, n  4; rifampin-bonded PTFE, n  22; autologous conduit, n  57) based on microbiology and
consideration for SMF for extensive soft tissue defects (n  43) or nonsterilized graft beds (n  40). Analysis of
microbiology, recurrent infection, vascular reconstruction, limb salvage, and mortality was completed over a mean
follow-up of 52 months (range: 12 to 132 months).
Results: Thirty-day mortality was 2% with two aortic graft infections dying from sepsis. Survival by life table analysis
at 1, 3, and 5 years was 94%, 92%, and 90%, respectively. Wound isolates were most commonly gram positive
organisms (n 58, 65%), with gram negative isolates and mixed infections accounting for 19% and 10%, respectively.
A single recurrent groin infection was documented at 30 days. Freedom from recurrent infection (n  6) at 1 and 5
years was 98% and 92% by life tables. Methicillen-resistant Staphylococcus aureus (MRSA) was involved for 50% of
reinfections. No amputations were attributable to uncontrolled VSSI and graft patency was 100% in surveillance
monitored patients.
Conclusion: These results suggest that selective utilization of SMF as part of SSD treatment plan in an attempt to achieve
graft bed sterilization can effectively control the complex infectious process allowing for potentially improved outcomes
for in situ or preservation graft salvage techniques. Lifelong graft surveillance is recommended. (J Vasc Surg 2007;46:
71-8.)Vascular surgical site infections (VSSI) threaten not
only graft patency, but often adversely influence both
limb salvage and mortality rates. Historically, these un-
favorable outcomes have been associated with the mor-
bidity of extensive graft removals and complex recon-
structions in groups of patients who typically have a
surplus of other medical comorbidities. Mortality rates
among series reporting these infections ranging from 9%
to 58% have been documented with limb loss rates
reported as high as 79%.1-5 Because each VSSI is unique
to patient’s degree of existing arterial occlusive disease
including previous vascular procedures, it remains diffi-
cult to adopt recommendations based solely on the type
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wise, examination of the utility of surgical adjuncts for
treating VSSI such as rotational muscle flaps are limited
by small series cohorts with variable vascular reconstruc-
tions and poor long-term follow-up.
Clinical experience has allowed some authors who treat
large numbers of these patients to investigate a variety of
factors and adjuncts that may provide improved outcomes
among this complicated group of patients.6-8 For some
time now, our tertiary University vascular practice has
addressed the issue of VSSI by focusing on identification of
causative pathogen and attempting to achieve wound ster-
ilization prior to definitive graft salvage or reconstruction.
To this end, we have investigated the use of a variety of
surgical adjuncts including staged surgical debridement,
antibiotic impregnated beads, parenteral antibiotics, and
use of muscle flap coverage in the treatment of VSSIs. This
report was developed to better define the actual incidence
of Sartorius muscle flap (SMF) required for complicated
wound coverage and determine the efficacy of SMF as part
of a wound sterilization treatment plan for addressing
VSSIs.
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Patients. A retrospective review of our vascular regis-
try identified 442 prosthetic VSSI treated over a 13-year
period (1994 to 2006). Of this group, 353 VSSIs did not
have SMF utilized as part of their treatment plan or had
combined intracavitary and extracavitary graft infections
and were excluded from detailed analysis. The remaining
89 VSSIs involved 86 patients (47 male, 39 female) who
presented with isolated grade III Szilagyi extracavitary in-
guinal prosthetic graft infections. Three patients had bilat-
eral groin infections associated with one aorto-bifemoral
and two femoral-femoral bypass grafts. Initial revasculariza-
tion procedures included: 24 aorto-bifemoral (ABF), 19
extra-anatomic bypasses (EAB), 31 infrainguinal bypasses,
and 12 combined inflow/outflow reconstructions. Dacron
grafts (n  36) were predominately used for ABF and
combined reconstructions while and polytetrafluoroethyl-
ene (PTFE) (n  50) composed the majority of EAB or
infrainguinal reconstructions (Table I). Atherosclerotic risk
stratification for the group is listed in Table II. Within the
cohort there were nine (10%) early (4 months), which
presented 6 to 28 days after the initial vascular procedure.
The time range for late appearing infections was more
difficult to define as the majority of patients were tertiary
referrals with incomplete medical records. Typically, pa-
Table I. Initial vascular procedures and occluded grafts
associated with VSSI
Bypass Material N  86 Occlusions (n  9)
Aorto-bifemoral Dacron 21 3†
(n  24) PTFE 3 1†
Extra-anatomic Dacron 4 1
(n  19) PTFE 15
Infrainguinal Dacron 2 1
(n  31) PTFE 29 2
Combined* Dacron 9 1
(n  12) PTFE 3
PTFE, Polytetrafluoroethylene; VSSI, vascular surgical site infections.
*Combined: both inflow and outflow prosthetic reconstructions were
present in groin at time of infection.
†Occluded graft limbs.
Table II. Atherosclerotic risk factors and patient
characteristics
Coronary artery disease 59 (69%)
Hypertension 75 (87%)
Ipsilateral vascular bypass 19 (22%)
Contralateral vascular bypass 12 (14%)
Contralateral major amputation 3 ( 3%)
Current smoker 30 (35%)
Tobacco use history 25 (29%)
Diabetes 32 (37%)
COPD* 10 (12%)
ESRD 2 ( 2%)
COPD, oxygen dependent and/or steroid dependent; ESRD, dialysis de-
pendent.tients presented with indolent symptoms as summarized inTable III. However, four patients presented with hemody-
namic instability, two with systemic inflammatory response
syndrome (SIRS) and two with para-anastomotic hemor-
rhage.
Methods. Our group has previously described our
selective algorithm for management of intracavitary and
extracavitary graft infections.6,10 All EAB and ABF infec-
tions completed CT imaging to exclude intracavitary or
axillary limb involvement, but 19 infrainguinal bypasses did
not have a CT scan as part of their initial evaluation because
the VSSI was not associated with a previous inflow proce-
dure, prosthetic infection, or showed no signs of distal
autologous bypass involvement. The extent of graft in-
volvement in this group was then determined at the time of
surgery based on graft incorporation and soft tissue find-
ings. All VSSIs received broad-spectrum parenteral antibi-
otics including coverage for Methicillen-resistant Staphylo-
coccus (MRSA) at admission. Intravenous antibiotic therapy
was adjusted according to culture and sensitivity reports
and in general parenteral antibiotics were continued 6
weeks after the final operation. Lifelong antibiotic suppres-
sion was not used in this group. We reserve use of lifetime
antibiotic suppression for patients withClostridium species,
or in individuals deemed to ill to undergo surgical manage-
ment.
Beginning in 2001, one author (D.F.B.) began using
antibiotic-loaded polymethylmethacrylate beads as an ad-
junct in the treatment of extracavitary prosthetic graft
infections. In this series, 12 patients had antibiotic beads
placed as part of their individualized treatment plan. When
antibiotic beads were placed during staged debridement
they were removed at the time of documented wound
sterilization or by postoperative day 7 of the patient’s last
procedure
Staged surgical debridement. Initial surgical de-
bridement took place at a mean interval of 2.3 days (range
1 to 5 days) and included excision of all grossly infected
tissue and perigraft tissue was swabbed for gram stain and
tissue cultures were also obtained. Routine graft bed pulse
lavage with Clorpactin (bleach) solution (4 gm/LNS) and
washout with “Brown Volcano” (1:1:1 Betadine (Purdue
Pharma, Stamford, Conn), hydrogen peroxide, sterile nor-
mal saline irrigation) was performed at each debridement.
Table III. Clinical findings and at presentation
Signs/Symptoms N  89 (%)
Sinus tract 30 (34%)
Cellulitis 25 (28%)
Perigraft fluid collection 24 (27%)
Psuedoaneurysm 10 (11%)
Systemic sepsis 5 ( 6%)
Bleeding psuedoaneurysm 2 ( 2%)
Fever/malaise 2 ( 2%)
Septic emboli 1 ( 1%)
Patent grafts 80 (90%)
Occluded grafts 9 (10%)The number of operations per patient varied (mean 2.6/
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clinical response to therapy and culture results. If additional
debridement was anticipated then only the skin and deep
dermal tissue was approximated if possible to prevent des-
iccation of the graft bed tissues. Multilayered wound clo-
sures and vascular reconstructions utilizing graft preserva-
tion, autologous tissue, or rifampin-bonded prosthetic
graft strategies were performed if the last culture revealed
no bacterial growth (aka: “wound sterilization”). For graft
beds with residual bacterial counts, but demonstrating a
lack of ongoing virulence as defined by an absence of
clinical signs of infection including leukocytosis, drainage,
necrotic tissue, or inflammation; final revascularization and
wound closure was addressed individually based on micro-
biology, revascularization history, available bypass conduit,
and patient comorbidities. In general, bacterial counts
102 colony forming units in wounds demonstrating clin-
ical progress was desirable before the final wound debride-
ment/revascularization.
Muscle flap construction. There were three basic in-
dications for SMF. Wounds with extensive soft tissue de-
fects (n 43, 48 %) received a flap procedure regardless of
wound microbiology. In this group, the muscle flap was
deemed necessary to provide a foundation for soft tissue
coverage of the femoral vasculature. Persistent postopera-
tive lymphoceles occurred in six VSSIs and were success-
fully treated with SMF. The remaining SMF (n 40, 45%)
involved wounds with late appearing infections that docu-
mented negative cultures after staged surgical debridement
(SSD) (n  11) or had initially virulent infections that
improved clinically after SSD but had persistently positive
tissue cultures (n  29) prior to SMF.
Application of SMF occurred at two distinct intervals.
Early flaps were placed in nine, four early (4 months) and
five late VSSIs, at the time of first debridement in the
setting of gross wound bed contamination. Four of these
early SMF were placed by the referring surgeon while the
other five had complex soft tissue wounds with a clinical
picture of severe native arterial and anastomotic inflamma-
tion, which required revascularization at time of the first
debridement. The remaining 80 patients had delayed ap-
plication of SMF (range 4 to 22 days; mean 9 days) with the
flap being placed at the time of documented wound steril-
ization or at the final revascularization when the graft bed
was free of gross signs of infection.
All four of the SMF placed at outside facilities had to be
taken down in order to provide additional soft tissue de-
bridement in an effort to clear the perigraft infection. None
of these four flaps were viable for repeat application and
alternative muscle flaps, (two rectus femoris and two graci-
lis) were used at the time of final wound closure. From the
remaining five early flaps, two developed some degree of
flap necrosis and failed during the staged treatment phase.
One of these wounds eventually had graft excision and EAB
with autologous tissue and did not require muscle flap
coverage. The remaining had a rectus muscle flap placed.
All the late SMFs were deemed viable with no history of
wound complications at 30 days, and no flap necrosis wasidentified at any procedure done for reinfected wounds
during the follow-up period.
RESULTS
Surgical site microbiology. Wound isolates were
most commonly gram positive organisms (n  58, 65%)
with gram negative isolates and mixed infections account-
ing for 19% and 10%, respectively. Single organism recovery
was most common (n 77, 87%) with nine VSSI infections
yielding two or more pathogens. Two graft beds had Can-
dida species recovered and no growth was present in three
VSSIs. Graft bed microbiology is summarized in Table IV.
According to chart review wound sterilization, defined
as negative cultures for the surgical site was documented in
52% (n  46) VSSIs. Graft beds with negative cultures at
final revascularization included six (13%) wounds with per-
sistent lymphoceles, 29 (63%) wounds with complex soft
tissue defects, and 11 (24%) wounds completing SSD.
Fifteen of these wounds with mixed pathogens cleared two
or more pathogens. Of the nine early graft infections, seven
achieved sterilization prior to revascularization. Thirty-nine
of 80 (49%) of late appearing VSSI attained sterilization.
The remaining 43 (48%) VSSIs improved clinically but
did not have negative cultures at the time of their final
operative procedure. Seven of these wounds with mixed
pathogens cleared one or more organisms, but not all. An
additional five developed nosocomial isolates during the
course of therapy (three MRSA, one Pseudomonas, one
Candida species). Fourteen nonsterile wounds were asso-
ciated with complex soft tissue defects and single isolates at
the time of SMF application. The remaining 17 nonsterile
wounds had reduced colony counts and demonstrated clin-
ical improvement after SSD and received simultaneous
revascularization with SMF as their final procedure.
Recurrent infection. Recurrent VSSIs occurred in
Table IV. Graft bed microbiology from 89 vascular
surgical site infections
Microorganisms
Initial isolates
(n  89)
Recurrent
infections
(n  6)
Gram  58 (65 %)
Staphylococcus species 49
S aureus 22
S epidermidis 13 1
Methicillin-resistant 14 3
Streptococcus 2
Enterococcus 6
Peptococcus 1
Gram  17 (19 %)
Pseudomonas aeruginosa 12
Klebsiella pneumonia 2 1
Escherichia coli 2
Serratia marcescens 1
Mixed gram / 9 (10%)
Candida species 2 (2%)
No growth 3 (3%) 1two of three (66%) patients initially treated with graft
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rifampin-bonded in situ graft replacement.
One early recurrent infection (30 days from SMF
application) developed in a patient with history of multiple
inflow procedures and was found to have an isolated seg-
ment of retained Dacron graft from a previous bypass
procedure. This graft segment was removed, and the pa-
tient was treated according to culture results and the SMF/
rifampin bonded PTFE interposition limb was salvaged.
Beyond 30 days, recurrent infection occurred in an addi-
tional five patients at a mean interval of 23 months (range 1
to 47 months). Reinfection rates by life table estimate were
2.3 % and 8 % at 1 and 5 years, respectively. Table IV lists
recurrent isolates and Table V summarizes freedom from
infection by life table. MRSA accounted for three recurrent
infections with a biform Staphylococcus andCandida species
infections accounting for two of the recurrences. The single
gram-negative recurrence (K pneumoniae) occurred in a
graft bed that initially had cleared a gram positive infection.
Among the late recurrences (30 days) there were two
graft preservations and three rifampin-bonded limb re-
placements. One late recurrence was treated with graft
excision and EAB, while the other four had graft excision
with autologous reconstruction in three and rifampin-
bonded limb replacement in one.
Vascular reconstruction. Four patients presented
with acute limb ischemia and early graft infection (one
ABF, one iliac artery occlusion, one femoral artery occlu-
sion, one femoral-infrageniculate bypasses) and required
emergent arterial revascularization at the time of their first
debridement. An additional five patients with one early and
four late VSSIs developed limb ischemia prior to wound
sterilization or clinical improvement of the graft bed, (two
ABF, two EAB, one femoral-infrageniculate bypass) neces-
sitating urgent revascularization. Among this group of nine
requiring emergent or urgent limb salvage, reconstructions
included two thrombectomies (one with a combined iliac
stent), three rifampin-bonded PTFE (one that later devel-
Table V. Life table analysis freedom from recurrent infect
Inter-val (mo)
No.VSSI
at risk
No. of
deaths
No. lost to
follow-up
Re
in
1 89 2 0
3 87 0 0
6 87 1 0
12 86 2 0
18 83 0 1
24 82 0 1
30 78 1 2
36 75 1 5
42 69 0 4
48 63 0 7
54 56 0 1
60 53 1 10
66 42 1 8
72 33 0 5
VSSI, Vascular surgical site infections; SE, standard error.oped a late MRSA reinfection and one of which was laterreplaced with autologous tissue due to ongoing infectious
concerns), and four graft excisions with autologous recon-
structions. There were two patients who had prolonged
ischemia prior to transfer that required below knee ampu-
tation despite successful inflow revascularization.
The remaining VSSIs, all presented with a history of
peripheral artery disease and chronic limb ischemia. Table
VI contrasts the initial and final vascular reconstructions.
Two patients required femoral-distal bypass procedure for
progression of infrageniculate atherosclerotic disease dur-
ing the follow-up period on the infected limb side while an
additional two patients had vein graft revisions (one bal-
nt
n
Interval recurrent
infection
Cumulative recurrent
infection SE (%)
98.9 98.9 0
100 98.9 1.1
100 98.9 1.1
98.8 97.7 1.5
98.8 96.5 1.8
98.8 95.3 2.4
100 95.3 2.4
98.6 93.9 2.7
100 93.9 2.8
98.3 92.2 3.3
98.3 92.2 3.5
98.3 92.2 3.6
98.3 92.2 4.0
98.3 92.2 4.5
Table VI. Initial and final vascular reconstructions
Initial VSSI Final vascular reconstruction
Aorto-bifemoral
(n  24)
Total graft excision and EAB 4
Partial graft-limb excision and
rifampin-PTFE
13
Partial graft-limb excision and
autologous bypass
7
Extra-anatomic
(n  19)
Graft preservation 1
Total graft excision and
autologous bypass
7
Partial graft excision and
rifampin-PTFE
3
Partial graft excision and
autologous bypass
8
Infrainguinal
(n  31)
Graft preservation 2
Total graft excision and PTFE
bypass
2
Total graft excision and
autologous bypass
27
Combined*
(n  12)
Partial graft excision and
rifampin-PTFE bypass
4
Partial graft excision and
autologous bypass
8
VSSI, Vascular surgical site infections; PTFE, polytetrafluoroethylene; EAB,
extra-anatomic bypasses.
*Combined: both inflow and outflow prosthetic reconstructions were
present in groin at time of infection.ion
curre
fectio
1
0
0
1
1
1
0
1
0
1
0
0
0
0loon angioplasty, one vein patch) during duplex surveil-
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knee amputations, the overall limb salvage rate has been
100% for those not lost to follow-up with graft patency rate
of 100% for those who remained in duplex surveillance.
Disposition. All surviving patients completed wound
closure or wound coverage with skin grafting at the time
discharge from the hospital. Mean hospital length of stay
was 17 days (range 6 to 112 days). Two patients presenting
with systemic inflammatory response syndrome (SIRS) and
aortic limb graft infection died within 30 days due to sepsis
and multisystem organ failure. According to medical
records, telephone contact, or Social Security Death Index,
seven additional deaths occurred over the follow-up period
(three cardiac two respiratory, one cancer, one unknown)
with three of these occurring in the first year of follow-up.
One of these was a respiratory death in the hospital at 54
days. Life table analysis is shown in Table VII reports one
and 5-year survival of 98% and 90%, respectively.
DISCUSSION
The long-established practice of total graft excision and
extra-anatomic revascularization has been challenged in an
effort to improve clinical outcomes in some subgroups of
patients. Certainly, among some infections such as aortoen-
teric erosions few other options are possible, while, the
virulent nature of gram negatives and antibiotic resistant
pathogens have been associated with generally poorer out-
comes.9,17 The often unpleasant consequences of total
graft excision and complex revascularization has prompted
surgical groups to investigate alternative treatment strate-
gies such as in situ reconstructions and graft preserva-
tion.6-9
In considering alternative revascularizations, we have
embraced the concept of “wound sterilization”, which has
matured over the last 5 years to become what we consider
the core component in the treatment of VSSI. Wound
sterilization is not a new innovation as other orthopedic
and reconstruction specialists have relied on a similar strat-
egy to treat complex prosthetic implant infections for some
Table VII. Life table analysis survival
Interval (mo) No.VSSI at risk No. of deaths No. lost to fol
1 89 2 0
3 87 0 0
6 87 1 0
12 86 2 0
18 83 0 1
24 82 0 1
30 78 1 2
36 75 1 5
42 69 0 4
48 63 0 7
54 56 0 1
60 53 1 10
66 42 1 8
72 33 0 5
VSSI, Vascular surgical site infections; SE, standard error.time now. The benefit of “wound sterilization” is based onthe premise that wounds with minimal bacterial coloniza-
tion will have less healing setbacks therefore improve the
clinical success rates. Application of this clinical pathway
(Fig) has resulted in improved wound sterilization rates
from just less than 50% to 87% in a recent consecutive VSSI
series.18 A query of our vascular database during the same
time period identified 234 grade II and III inguinal VSSIs
that did not have SMF as part of their treatment plan.While
the diversity of presentation and length of follow-up make
for difficult direct statistical comparison, the overall reinfec-
tion rate for this group was 9% (22/234) compared with a
7% reinfection rate in VSSI treated with adjunctive SMF
suggesting that SMF alone may not provide any significant
protective benefit against reinfection.
In the current, series we are able to clear a variety of
wound infections, including the traditionally more stub-
born gram negative, polymicrobial, and antibiotic-resistant
pathogens. Negative wound cultures were often achieved
before the application of SMF suggesting that SMF is not
required for wound sterilization. Considering the reinfec-
tions seen in this series, five of six were associated with
wounds that did not achieve negative cultures and 50%
involved antibiotic-resistant pathogens in the setting of
nonautologous reconstructions. Over the last 6 years, we
have noted a distinct trend towards an increased incidence
of infectious recurrences involving resistant pathogens es-
pecially among graft preservation or prosthetic in situ re-
constructions.6,10,18
As a regional referral center, we are often unable to
control the presentation and previous vascular history of
the patients who present to our facility with VSSI making
randomization into treatment arms impractical. Likewise,
our catchment area is large making regular office evalua-
tions difficult and infrequent as evidenced by more than
50% of SMFs unavailable for evaluation at 6 years. How-
ever, the standard error of the mean (SEM) remains 10%
during that time period. Nonetheless, as a subgroup of
VSSIs, this retrospective clinical review is exposed to the
p Interval survival (%) Cumulative survival (%) SE (%)
97.7 97.7 0
100.0 97.7 1.5
98.8 96.5 1.8
97.7 94.2 2.5
100 94.2 2.5
100 94.2 2.5
98.7 92.9 2.8
98.6 91.5 3.0
100 91.5 3.1
100 91.5 3.3
100 91.5 3.5
98.2 89.7 3.9
97.4 87.0 4.8
97.4 87.0 5.5low-utraditional statistical weaknesses known to such repots.
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beyond soft tissue coverage? Application of a muscle flap to
provide closure of a complex wound or coverage of a
vascular graft bed is not a novel idea.4,11,12 Surprisingly,
contemporary reports onmuscle flap coverage of prosthetic
VSSI in general contain small cohorts of patients who are
offered an assortment of flap procedures applied to a variety
of vascular beds andmuch of this work has not been verified
by vascular surgeons who routinely treat VSSI.
Some authors have advocated early flap application but
the optimum timing of flap construction is not well de-
fined.13,14 Treiman et al and others have suggested that
routine rotational or free flap muscle coverage should be
utilized early in the treatment plan in order to reduce the
morbidity associated with VSSIs.15 In this series, early
application of SMF prior to local control of infection risked
loss of the flap. Although there were much fewer early graft
applications, in each instance where graft bed infection was
not controlled, the SMF was not fit for reapplication or was
a risk for failure due to the ongoing infectious process
necessitating removal of portions of the flap at each serial
Fig. Patient-specific treatment algorithm for VSSI bas
wound.debridement. Once released from its origin, the muscleremodels in both size and function. The motor function of
the muscle has now been replaced with a designation as
deep tissue coverage improving both leukocyte function
and oxygen tension to the wound thus impairing bacterial
replication.16 This role of the SMF as wound protector and
healer becomes disrupted at each serial debridement as
portions of the muscle become devitalized and do not
recover as the muscle naturally atrophies while failure to
clear or reduce the graft bed of bacterial contamination
risks reinfection and limb loss. Timing of muscle flap appli-
cation then becomes as critical as maintaining proper blood
supply to the flap in terms of technical success if we expect
the flap to not only cover the wound but aid in bacterial
eradication.
The SMF has been criticized as a poor choice of flap
because it is often associated with the infected graft bed.5 In
general, the majority of VSSI infections are indolent and
perigraft in location. They do not routinely involve exten-
sive fasciaitis or myonecrosis at presentation. The strategy
of staged graft bed debridements to remove all grossly
infected soft tissue, which primarily includes only skin and
aft bed microbiology and clinical improvement of theed grsubcutaneous tissue, allows for optimum control of local
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culture negative or at a minimum will have a significantly
reduced bacterial count. This important alteration in the
wound environment enhances the protective effects of the
rotated muscle flap. Because of the relative ease in complet-
ing a rotational SMF, our group has found it generally
unnecessary to use alternative rotational muscle or free
muscle flaps. In this series, we used two rotational gracilis
and three rotational rectus femoris flaps to treat failed early
applied SMFs.
As we have sought to clinically validate this clinical
pathway, several distinct trends in our successes and failures
have become evident. First, we now only consider graft
preservation for only early VSSIs. We have regularly noted
recurrent infections when using this technique with
wounds harboring late infections even when including
SMF as an adjunct to graft preservation. Second, the addi-
tion of antibiotic-loaded beads to SSD has resulted in-
creased wound sterilization rates. Although the application
of antibiotic beads requires additional long- term study,
our most recent clinical review confers a relative safety to
the techniques and documents improved wound steriliza-
tion compared with previous infections we have treated
without beads.18 And finally, proper timing and selective
application of SMF results in a viable rotational flap that will
facilitate improved wound healing rates with low proce-
dural morbidity/mortality.
CONCLUSION
Because the extent of clinically significant vascular dis-
ease, history of vascular reconstructions, and medical co-
morbidities are often diverse among vascular patients, our
vascular group has emphasized an individualized treatment
algorithm that treats VSSI by utilizing graft preservation, in
situ limb replacement as well as graft excision methods
(Table VIII). By attempting to achieve a sterilized graft bed
prior to a graft preservation or revascularization, we believe
that we give both the traditional and more contemporary
treatment methods the best chance for favorable outcomes.
Clearly, rotational muscle flaps are not required for every
Table VIII. Criteria for individualized revascularization a
and final graft bed cultures
Routine application SMF
Complex
soft tissue
defect
Persistent
lymphocele
Wound
sterilizatio
Graft preservation
(early infection) yes Yes yes
Rifampin-bonded in
situ PTFE yes Yes no
Autologous
revascularization yes Yes no
*Not a recommended reconstruction option according to graft bed microb
†Consideration for SMF in the setting of virulent infection.VSSI, but they should be considered beyond the simpleprinciple of providing soft tissue coverage for large wounds
or persistent lymphoceles. This is especially true when a in
situ prosthetic or graft preservation strategy is being em-
ployed especially in the setting of more virulent pathogens
such as polymicrobial, gram negative, or antibiotic-resistant
VSSIs. Knowledge of the technical points associated with
the procedure as well as proper timing for application
ensures graft viability. Lifelong graft surveillance should be
compulsory regardless of the final revascularization plan
among individuals at risk for infection.
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